Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Cuttino (2016)
5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trialBreast Diseases: A Year Book Quarterly, 27
I. Meattini, L. Marrazzo, C. Saieva, I. Desideri, V. Scotti, G. Simontacchi, P. Bonomo, D. Greto, M. Mangoni, S. Scoccianti, S. Lucidi, L. Paoletti, M. Fambrini, M. Bernini, L. Sanchez, L. Orzalesi, J. Nori, S. Bianchi, S. Pallotta, L. Livi (2020)
Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
( Haviland JS , Owen JR , Dewar JA , et al. The UKStandardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086–94.24055415)
Haviland JS , Owen JR , Dewar JA , et al. The UKStandardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086–94.24055415Haviland JS , Owen JR , Dewar JA , et al. The UKStandardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086–94.24055415, Haviland JS , Owen JR , Dewar JA , et al. The UKStandardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086–94.24055415
( Çerkeşli ZAK , Kayalı FI , Habiboğlu R . Dosimetric comparison of three‐dimensional conformal radiotherapy, forward‐planned intensity modulated radiotherapy and volumetric modulated arc therapy in intact breast radiotherapy without lymphatic irradiation. Acta Oncol Turcica 2019; 52: 293–302.)
Çerkeşli ZAK , Kayalı FI , Habiboğlu R . Dosimetric comparison of three‐dimensional conformal radiotherapy, forward‐planned intensity modulated radiotherapy and volumetric modulated arc therapy in intact breast radiotherapy without lymphatic irradiation. Acta Oncol Turcica 2019; 52: 293–302.Çerkeşli ZAK , Kayalı FI , Habiboğlu R . Dosimetric comparison of three‐dimensional conformal radiotherapy, forward‐planned intensity modulated radiotherapy and volumetric modulated arc therapy in intact breast radiotherapy without lymphatic irradiation. Acta Oncol Turcica 2019; 52: 293–302., Çerkeşli ZAK , Kayalı FI , Habiboğlu R . Dosimetric comparison of three‐dimensional conformal radiotherapy, forward‐planned intensity modulated radiotherapy and volumetric modulated arc therapy in intact breast radiotherapy without lymphatic irradiation. Acta Oncol Turcica 2019; 52: 293–302.
L. Valle, S. Agarwal, K. Bickel, H. Herchek, D. Nalepinski, N. Kapadia (2017)
Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trialsBreast Cancer Research and Treatment, 162
J. Owen, A. Ashton, J. Bliss, J. Homewood, C. Harper, J. Hanson, J. Haviland, S. Bentzen, J. Yarnold (2006)
Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial.The Lancet. Oncology, 7 6
( Vaidya JS , Wenz F , Bulsara M , et al. Risk‐adapted targeted intraoperative radiotherapy versus whole‐breast radiotherapy for breast cancer: 5‐year results for local control and overall survival from the TARGIT‐A randomised trial. Lancet 2014; 383: 603–13.24224997)
Vaidya JS , Wenz F , Bulsara M , et al. Risk‐adapted targeted intraoperative radiotherapy versus whole‐breast radiotherapy for breast cancer: 5‐year results for local control and overall survival from the TARGIT‐A randomised trial. Lancet 2014; 383: 603–13.24224997Vaidya JS , Wenz F , Bulsara M , et al. Risk‐adapted targeted intraoperative radiotherapy versus whole‐breast radiotherapy for breast cancer: 5‐year results for local control and overall survival from the TARGIT‐A randomised trial. Lancet 2014; 383: 603–13.24224997, Vaidya JS , Wenz F , Bulsara M , et al. Risk‐adapted targeted intraoperative radiotherapy versus whole‐breast radiotherapy for breast cancer: 5‐year results for local control and overall survival from the TARGIT‐A randomised trial. Lancet 2014; 383: 603–13.24224997
N. Rodríguez, X. Sanz, J. Dengra, P. Foro, I. Membrive, A. Reig, J. Quera, E. Fernández-Velilla, O. Pera, J. Lio, J. Lozano, M. Algara (2013)
Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation.International journal of radiation oncology, biology, physics, 87 5
D. Spooner, D. Stocken, Sarah Jordan, S. Bathers, J. Dunn, C. Jevons, L. Dodson, J. Morrison, G. Oates, R. Grieve (2009)
A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancer.Clinical oncology (Royal College of Radiologists (Great Britain)), 24 10
Adrian Brunt, Joanne Haviland, Duncan Wheatley, Mark Sydenham, Abdulla Alhasso, D. Bloomfield, Charlie Chan, Mark Churn, Suzy Cleator, Charlotte Coles, A. Goodman, A. Harnett, Penelope Hopwood, Anna Kirby, C. Kirwan, Carolyn Morris, Z. Nabi, Elinor Sawyer, Navita Somaiah, Liba Stones, I. Syndikus, Judith Bliss, John Yarnold, Abdulla Cha, Abdulla Alhasso, A. Armstrong, Judith Bliss, D. Bloomfield, J. Bowen, M. Brunt, Charlie Chan, H. Chantler, Mark Churn, Suzy Cleator, Charlotte Coles, E. Donovan, A. Goodman, S. Griffin, Jo Haviland, Penny Hopwood, Anna Kirby, J. Kirk, C. Kirwan, M. Maclennan, Carolyn Morris, Z. Nabi, Elinor Sawyer, M. Sculphur, J. Sinclair, Navita Somaiah, Liba Stones, Mark Sydenham, I. Syndikus, Jean Tremlett, K. Venables, Duncan Wheatley, John Yarnold (2020)
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trialLancet (London, England), 395
C. Yashar, A. Khan, B. Haffty, P. Chen, Z. Yehia, F. Vicini, M. Kowzun, T. Quinn, D. Scanderbeg, L. Simon, R. Kuske (2021)
Three-Fraction TRIUMPH-T Brachytherapy for Delivery of APBI Offers Effective Disease Control With Minimal Late Toxicity.International journal of radiation oncology, biology, physics, 111 3S
Z. Cerkesli, F. Kayali, R. Habi̇boğlu (2019)
Dosimetric Comparison of Three-Dimensional Conformal Radiotherapy, Forward-Planned Intensity Modulated Radiotherapy and Volumetric Modulated Arc Therapy in Intact Breast Radiotherapy without Lymphatic IrradiationActa Oncologica Turcica
( Rodriguez N , Sanz X , Dengra J , et al. Five‐year outcomes, cosmesis and toxicity with 3‐dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2013; 87: 1051–7.24161420)
Rodriguez N , Sanz X , Dengra J , et al. Five‐year outcomes, cosmesis and toxicity with 3‐dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2013; 87: 1051–7.24161420Rodriguez N , Sanz X , Dengra J , et al. Five‐year outcomes, cosmesis and toxicity with 3‐dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2013; 87: 1051–7.24161420, Rodriguez N , Sanz X , Dengra J , et al. Five‐year outcomes, cosmesis and toxicity with 3‐dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2013; 87: 1051–7.24161420
( Polgár C , Major T , Takácsi‐Nagy Z , Fodor J . Breast‐conserving surgery followed by partial or whole breast irradiation: Twenty‐year results of a phase 3 clinical study. Int J Radiat Oncol Biol Phys 2021; 109: 998–1006.33186620)
Polgár C , Major T , Takácsi‐Nagy Z , Fodor J . Breast‐conserving surgery followed by partial or whole breast irradiation: Twenty‐year results of a phase 3 clinical study. Int J Radiat Oncol Biol Phys 2021; 109: 998–1006.33186620Polgár C , Major T , Takácsi‐Nagy Z , Fodor J . Breast‐conserving surgery followed by partial or whole breast irradiation: Twenty‐year results of a phase 3 clinical study. Int J Radiat Oncol Biol Phys 2021; 109: 998–1006.33186620, Polgár C , Major T , Takácsi‐Nagy Z , Fodor J . Breast‐conserving surgery followed by partial or whole breast irradiation: Twenty‐year results of a phase 3 clinical study. Int J Radiat Oncol Biol Phys 2021; 109: 998–1006.33186620
( Strnad V , Ott OJ , Hildebrandt G , et al. 5‐year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole‐breast irradiation with boost after breast‐conserving surgery for low‐risk invasive and in‐situ carcinoma of the female breast: a randomised, phase 3, non‐inferiority trial. Lancet 2016; 387: 229–38.26494415)
Strnad V , Ott OJ , Hildebrandt G , et al. 5‐year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole‐breast irradiation with boost after breast‐conserving surgery for low‐risk invasive and in‐situ carcinoma of the female breast: a randomised, phase 3, non‐inferiority trial. Lancet 2016; 387: 229–38.26494415Strnad V , Ott OJ , Hildebrandt G , et al. 5‐year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole‐breast irradiation with boost after breast‐conserving surgery for low‐risk invasive and in‐situ carcinoma of the female breast: a randomised, phase 3, non‐inferiority trial. Lancet 2016; 387: 229–38.26494415, Strnad V , Ott OJ , Hildebrandt G , et al. 5‐year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole‐breast irradiation with boost after breast‐conserving surgery for low‐risk invasive and in‐situ carcinoma of the female breast: a randomised, phase 3, non‐inferiority trial. Lancet 2016; 387: 229–38.26494415
B. Offersen, J. Alsner, H. Nielsen, E. Jakobsen, M. Nielsen, M. Krause, L. Stenbygaard, I. Mjaaland, A. Schreiber, U. Kasti, J. Overgaard (2020)
Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
( Coles CE , Griffin CL , Kirby AM , et al. Partial breast radiotherapy after breast conservation surgery for patients with early breast cancer (UKIMPORT LOW trial): 5‐year results from a multicentre, randomised, controlled phase 3, non‐inferiority trial. Lancet 2017; 930: 1048–60.)
Coles CE , Griffin CL , Kirby AM , et al. Partial breast radiotherapy after breast conservation surgery for patients with early breast cancer (UKIMPORT LOW trial): 5‐year results from a multicentre, randomised, controlled phase 3, non‐inferiority trial. Lancet 2017; 930: 1048–60.Coles CE , Griffin CL , Kirby AM , et al. Partial breast radiotherapy after breast conservation surgery for patients with early breast cancer (UKIMPORT LOW trial): 5‐year results from a multicentre, randomised, controlled phase 3, non‐inferiority trial. Lancet 2017; 930: 1048–60., Coles CE , Griffin CL , Kirby AM , et al. Partial breast radiotherapy after breast conservation surgery for patients with early breast cancer (UKIMPORT LOW trial): 5‐year results from a multicentre, randomised, controlled phase 3, non‐inferiority trial. Lancet 2017; 930: 1048–60.
Asma Waheed, S. Butt, Alia Ishtiaq, M. Mansha, Sana Mehreen, Mohsin Raza, Muhammad Yousaf (2021)
Dosimetric Comparison of Whole Breast Radiotherapy Using Field-in-Field and Volumetric Modulated Arc Therapy Techniques in Left-Sided Breast Cancer PatientsCureus, 13
( Periasamy K , Karunanithi G , Cholayil S , Dharanipragada K , Neelakanadan V . Dosimetric comparison between interstitial brachytherapy and volumetric‐modulated arc therapy for tumour bed boost in breast cancer. J Contemp Brachytherapy 2021; 13: 302–9.34122570)
Periasamy K , Karunanithi G , Cholayil S , Dharanipragada K , Neelakanadan V . Dosimetric comparison between interstitial brachytherapy and volumetric‐modulated arc therapy for tumour bed boost in breast cancer. J Contemp Brachytherapy 2021; 13: 302–9.34122570Periasamy K , Karunanithi G , Cholayil S , Dharanipragada K , Neelakanadan V . Dosimetric comparison between interstitial brachytherapy and volumetric‐modulated arc therapy for tumour bed boost in breast cancer. J Contemp Brachytherapy 2021; 13: 302–9.34122570, Periasamy K , Karunanithi G , Cholayil S , Dharanipragada K , Neelakanadan V . Dosimetric comparison between interstitial brachytherapy and volumetric‐modulated arc therapy for tumour bed boost in breast cancer. J Contemp Brachytherapy 2021; 13: 302–9.34122570
( Whelan TJ , Pignol JP , Levine MN , et al. Long term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513–20.20147717)
Whelan TJ , Pignol JP , Levine MN , et al. Long term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513–20.20147717Whelan TJ , Pignol JP , Levine MN , et al. Long term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513–20.20147717, Whelan TJ , Pignol JP , Levine MN , et al. Long term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513–20.20147717
K. Periasamy, G. Karunanithi, S. Cholayil, K. Dharanipragada, Vijayprabhu Neelakanadan (2021)
Dosimetric comparison between interstitial brachytherapy and volumetric-modulated arc therapy for tumor bed boost in breast cancerJournal of Contemporary Brachytherapy, 13
C. Polgár, T. Major, Z. Takácsi-Nagy, J. Fodor (2020)
Breast-Conserving Surgery followed by Partial or Whole Breast Irradiation: Twenty-Year Results of a Phase III Clinical Study.International journal of radiation oncology, biology, physics
J. Vaidya, F. Wenz, M. Bulsara, J. Tobias, D. Joseph, M. Keshtgar, H. Flyger, S. Massarut, M. Alvarado, C. Saunders, W. Eiermann, M. Metaxas, E. Sperk, M. Sütterlin, Douglas Brown, L. Esserman, M. Roncadin, A. Thompson, J. Dewar, H. Holtveg, S. Pigorsch, M. Falzon, E. Harris, A. Matthews, C. Brew-Graves, I. Potyka, T. Corica, N. Williams, M. Baum (2014)
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trialThe Lancet, 383
(2013)
The UKStandardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
( Khosla D , Kapoor R , Rana S , et al. Dosimetric comparison of three‐dimensional conformal radiotherapy (3DCRT) and volumetric modulated arc therapy (VMAT) plans for hypofractionated whole breast and regional nodes irradiation in breast cancer patients following breast conservative surgery. Int J Radiat Oncol Biol Phys 2020; 108: E321.)
Khosla D , Kapoor R , Rana S , et al. Dosimetric comparison of three‐dimensional conformal radiotherapy (3DCRT) and volumetric modulated arc therapy (VMAT) plans for hypofractionated whole breast and regional nodes irradiation in breast cancer patients following breast conservative surgery. Int J Radiat Oncol Biol Phys 2020; 108: E321.Khosla D , Kapoor R , Rana S , et al. Dosimetric comparison of three‐dimensional conformal radiotherapy (3DCRT) and volumetric modulated arc therapy (VMAT) plans for hypofractionated whole breast and regional nodes irradiation in breast cancer patients following breast conservative surgery. Int J Radiat Oncol Biol Phys 2020; 108: E321., Khosla D , Kapoor R , Rana S , et al. Dosimetric comparison of three‐dimensional conformal radiotherapy (3DCRT) and volumetric modulated arc therapy (VMAT) plans for hypofractionated whole breast and regional nodes irradiation in breast cancer patients following breast conservative surgery. Int J Radiat Oncol Biol Phys 2020; 108: E321.
( Yashar C , Khan AJ , Haffty BG Jr , et al. Three‐fraction Triumph‐T brachytherapy for delivery of APBI offers effective disease control with minimal late toxicity. Int J Radiat Oncol Biol Phys 2021; 111: S7.)
Yashar C , Khan AJ , Haffty BG Jr , et al. Three‐fraction Triumph‐T brachytherapy for delivery of APBI offers effective disease control with minimal late toxicity. Int J Radiat Oncol Biol Phys 2021; 111: S7.Yashar C , Khan AJ , Haffty BG Jr , et al. Three‐fraction Triumph‐T brachytherapy for delivery of APBI offers effective disease control with minimal late toxicity. Int J Radiat Oncol Biol Phys 2021; 111: S7., Yashar C , Khan AJ , Haffty BG Jr , et al. Three‐fraction Triumph‐T brachytherapy for delivery of APBI offers effective disease control with minimal late toxicity. Int J Radiat Oncol Biol Phys 2021; 111: S7.
D. Khosla, R. Kapoor, S. Rana, P. Tomar, K. Periasamy, R. Madan, S. Goyal, N. Kumar (2020)
Dosimetric Comparison of Three-Dimensional Conformal Radiotherapy (3DCRT) and Volumetric Modulated Arc Therapy (VMAT) Plans for Hypofractionated Whole Breast and Regional Nodes Irradiation in Breast Cancer Patients Following Breast Conservative SurgeryInternational Journal of Radiation Oncology Biology Physics, 108
(2021)
Breastconserving surgery followed by partial or whole breast irradiation: Twenty-year results of a phase 3 clinical study
A. Piras, S. Menna, A. D’Aviero, F. Marazzi, A. Mazzini, D. Cusumano, M. Massaccesi, G. Mattiucci, A. Daidone, V. Valentini, L. Boldrini (2021)
New fractionations in breast cancer: a dosimetric study of 3D‐CRT versus VMATJournal of Medical Radiation Sciences, 69
( Piras A , Menna S , D'Aviero A , et al. New fractionations in breast cancer: a dosimetric study of 3D‐CRT versus VMAT. J Med Radiat Sci 2022; 69: 227–35. 10.1002/jmrs.530 )
Piras A , Menna S , D'Aviero A , et al. New fractionations in breast cancer: a dosimetric study of 3D‐CRT versus VMAT. J Med Radiat Sci 2022; 69: 227–35. 10.1002/jmrs.530Piras A , Menna S , D'Aviero A , et al. New fractionations in breast cancer: a dosimetric study of 3D‐CRT versus VMAT. J Med Radiat Sci 2022; 69: 227–35. 10.1002/jmrs.530 , Piras A , Menna S , D'Aviero A , et al. New fractionations in breast cancer: a dosimetric study of 3D‐CRT versus VMAT. J Med Radiat Sci 2022; 69: 227–35. 10.1002/jmrs.530
B. Haffty (2010)
Long-Term Results of Hypofractionated Radiation Therapy for Breast CancerYearbook of Oncology, 2010
( Valle LF , Agarwal S , Bickel KE , et al. Hypofractionated whole breast of radiotherapy in breast conservation for early stage breast cancer: a systematic review and meta‐analysis of randomized trials. Breast Cancer Res Treat 2017; 162: 409–17.28160158)
Valle LF , Agarwal S , Bickel KE , et al. Hypofractionated whole breast of radiotherapy in breast conservation for early stage breast cancer: a systematic review and meta‐analysis of randomized trials. Breast Cancer Res Treat 2017; 162: 409–17.28160158Valle LF , Agarwal S , Bickel KE , et al. Hypofractionated whole breast of radiotherapy in breast conservation for early stage breast cancer: a systematic review and meta‐analysis of randomized trials. Breast Cancer Res Treat 2017; 162: 409–17.28160158, Valle LF , Agarwal S , Bickel KE , et al. Hypofractionated whole breast of radiotherapy in breast conservation for early stage breast cancer: a systematic review and meta‐analysis of randomized trials. Breast Cancer Res Treat 2017; 162: 409–17.28160158
( Offersen BV , Alsner J , Nielsen HM , et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomised Phase III trial: the DBCG HYPO Trial. J Clin Oncol 2020; 38: 3615–25.32910709)
Offersen BV , Alsner J , Nielsen HM , et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomised Phase III trial: the DBCG HYPO Trial. J Clin Oncol 2020; 38: 3615–25.32910709Offersen BV , Alsner J , Nielsen HM , et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomised Phase III trial: the DBCG HYPO Trial. J Clin Oncol 2020; 38: 3615–25.32910709, Offersen BV , Alsner J , Nielsen HM , et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomised Phase III trial: the DBCG HYPO Trial. J Clin Oncol 2020; 38: 3615–25.32910709
( Olivotto IA , Whelan TJ , Parpia S , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three‐dimensional conformal external beam radiotherapy. J Clin Oncol 2013; 31: 4038–45.23835717)
Olivotto IA , Whelan TJ , Parpia S , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three‐dimensional conformal external beam radiotherapy. J Clin Oncol 2013; 31: 4038–45.23835717Olivotto IA , Whelan TJ , Parpia S , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three‐dimensional conformal external beam radiotherapy. J Clin Oncol 2013; 31: 4038–45.23835717, Olivotto IA , Whelan TJ , Parpia S , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three‐dimensional conformal external beam radiotherapy. J Clin Oncol 2013; 31: 4038–45.23835717
U. Veronesi, R. Orecchia, P. Maisonneuve, G. Viale, N. Rotmensz, C. Sangalli, A. Luini, P. Veronesi, V. Galimberti, S. Zurrida, M. Leonardi, R. Lazzari, F. Cattani, O. Gentilini, M. Intra, P. Caldarella, B. Ballardini (2013)
Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial.The Lancet. Oncology, 14 13
( Waheed A , Butt S , Ishtiaq A , et al. Dosimetric comparison of whole breast radiotherapy using field‐in‐field and volumetric modulated arc therapy techniques in left‐sided breast cancer patients. Cureus 2021; 13: e15732.34285843)
Waheed A , Butt S , Ishtiaq A , et al. Dosimetric comparison of whole breast radiotherapy using field‐in‐field and volumetric modulated arc therapy techniques in left‐sided breast cancer patients. Cureus 2021; 13: e15732.34285843Waheed A , Butt S , Ishtiaq A , et al. Dosimetric comparison of whole breast radiotherapy using field‐in‐field and volumetric modulated arc therapy techniques in left‐sided breast cancer patients. Cureus 2021; 13: e15732.34285843, Waheed A , Butt S , Ishtiaq A , et al. Dosimetric comparison of whole breast radiotherapy using field‐in‐field and volumetric modulated arc therapy techniques in left‐sided breast cancer patients. Cureus 2021; 13: e15732.34285843
( Meattini I , Marrazzo L , Saieva C , et al. Accelerated partial‐breast irradiation compared with whole‐breast irradiation for early breast cancer: long term results of the randomized Phase III APBI‐IMRT‐Florence trial. J Clin Oncol 2020; 38: 4175–83.32840419)
Meattini I , Marrazzo L , Saieva C , et al. Accelerated partial‐breast irradiation compared with whole‐breast irradiation for early breast cancer: long term results of the randomized Phase III APBI‐IMRT‐Florence trial. J Clin Oncol 2020; 38: 4175–83.32840419Meattini I , Marrazzo L , Saieva C , et al. Accelerated partial‐breast irradiation compared with whole‐breast irradiation for early breast cancer: long term results of the randomized Phase III APBI‐IMRT‐Florence trial. J Clin Oncol 2020; 38: 4175–83.32840419, Meattini I , Marrazzo L , Saieva C , et al. Accelerated partial‐breast irradiation compared with whole‐breast irradiation for early breast cancer: long term results of the randomized Phase III APBI‐IMRT‐Florence trial. J Clin Oncol 2020; 38: 4175–83.32840419
( Vicini FA , Cecchini RS , White JR , et al. Long‐term primary results of accelerated partial breast irradiation after breast conserving surgery for early‐stage breast cancer: a randomised, Phase 3, equivalence trial. Lancet 2019; 394: 2155–64.31813636)
Vicini FA , Cecchini RS , White JR , et al. Long‐term primary results of accelerated partial breast irradiation after breast conserving surgery for early‐stage breast cancer: a randomised, Phase 3, equivalence trial. Lancet 2019; 394: 2155–64.31813636Vicini FA , Cecchini RS , White JR , et al. Long‐term primary results of accelerated partial breast irradiation after breast conserving surgery for early‐stage breast cancer: a randomised, Phase 3, equivalence trial. Lancet 2019; 394: 2155–64.31813636, Vicini FA , Cecchini RS , White JR , et al. Long‐term primary results of accelerated partial breast irradiation after breast conserving surgery for early‐stage breast cancer: a randomised, Phase 3, equivalence trial. Lancet 2019; 394: 2155–64.31813636
F. Vicini, R. Cecchini, J. White, D. Arthur, T. Julian, R. Rabinovitch, R. Kuske, P. Ganz, D. Parda, M. Scheier, K. Winter, S. Paik, H. Kuerer, L. Vallow, L. Pierce, E. Mamounas, B. McCormick, J. Costantino, H. Bear, I. Germain, G. Gustafson, L. Grossheim, I. Petersen, R. Hudes, W. Curran, J. Bryant, N. Wolmark (2019)
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trialThe Lancet, 394
( Owen JR , Ashton A , Bliss JM , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomized trial. Lancet Oncol 2006; 7: 467–71.16750496)
Owen JR , Ashton A , Bliss JM , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomized trial. Lancet Oncol 2006; 7: 467–71.16750496Owen JR , Ashton A , Bliss JM , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomized trial. Lancet Oncol 2006; 7: 467–71.16750496, Owen JR , Ashton A , Bliss JM , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomized trial. Lancet Oncol 2006; 7: 467–71.16750496
( Brunt AM , Haviland JS , Wheatley DA , et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST‐Forward): 5‐year efficacy and late normal tissue effects results from a multicentre, non‐inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613–26.32580883)
Brunt AM , Haviland JS , Wheatley DA , et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST‐Forward): 5‐year efficacy and late normal tissue effects results from a multicentre, non‐inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613–26.32580883Brunt AM , Haviland JS , Wheatley DA , et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST‐Forward): 5‐year efficacy and late normal tissue effects results from a multicentre, non‐inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613–26.32580883, Brunt AM , Haviland JS , Wheatley DA , et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST‐Forward): 5‐year efficacy and late normal tissue effects results from a multicentre, non‐inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613–26.32580883
C. Coles, C. Griffin, A. Kirby, J. Titley, R. Agrawal, A. Alhasso, I. Bhattacharya, A. Brunt, L. Ciurlionis, C. Chan, E. Donovan, M. Emson, A. Harnett, J. Haviland, P. Hopwood, M. Jefford, R. Kaggwa, E. Sawyer, I. Syndikus, Y. Tsang, D. Wheatley, M. Wilcox, J. Yarnold, J. Bliss, Wail E, W. Sarakbi, S. Barber, G. Barnett, P. Bliss, J. Dewar, D. Eaton, S. Ebbs, I. Ellis, P. Evans, E. Harris, H. James, C. Kirwan, J. Kirk, H. Mayles, A. McIntyre, J. Mills, A. Poynter, E. Provenzano, C. Rawlings, M. Sculpher, G. Sumo, M. Sydenham, A. Tutt, N. Twyman, K. Venables, A. Winship, J. Winstanley, G. Wishart, A. Thompson (2017)
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trialLancet (London, England), 390
( Spooner D , Stocken DD , Jordan S , et al. A randomised controlled trial to evaluate both the role and optimal fractionation of radiotherapy in the conservative management of early breast cancer. Clin Oncol 2012; 24: 697–706.)
Spooner D , Stocken DD , Jordan S , et al. A randomised controlled trial to evaluate both the role and optimal fractionation of radiotherapy in the conservative management of early breast cancer. Clin Oncol 2012; 24: 697–706.Spooner D , Stocken DD , Jordan S , et al. A randomised controlled trial to evaluate both the role and optimal fractionation of radiotherapy in the conservative management of early breast cancer. Clin Oncol 2012; 24: 697–706., Spooner D , Stocken DD , Jordan S , et al. A randomised controlled trial to evaluate both the role and optimal fractionation of radiotherapy in the conservative management of early breast cancer. Clin Oncol 2012; 24: 697–706.
( Veronesi U , Orecchia R , Maisonneuve P , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14: 1269–77.24225155)
Veronesi U , Orecchia R , Maisonneuve P , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14: 1269–77.24225155Veronesi U , Orecchia R , Maisonneuve P , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14: 1269–77.24225155, Veronesi U , Orecchia R , Maisonneuve P , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14: 1269–77.24225155
I. Olivotto, T. Whelan, S. Parpia, Do-Hoon Kim, T. Berrang, P. Truong, I. Kong, B. Cochrane, A. Nichol, I. Roy, I. Germain, M. Akra, M. Reed, A. Fyles, T. Trotter, F. Perera, W. Beckham, M. Levine, J. Julian (2013)
Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 32
Adjuvant external beam radiation therapy following breast‐conserving surgery is an integral component of treatment for patients diagnosed with early breast cancer. For many years, the established international standard has been the delivery of 25 daily fractions of 2 Gy encompassing the entire breast over 5 weeks. However, there is now established mature evidence in the form of 5 randomised clinical trials and a meta‐analysis1–6 for moderately hypofractionated radiation therapy of 15 to 16 fractions of 2.6 Gy. These have all demonstrated non‐inferior outcomes comparing the 3‐week regimen to the traditional 5–6‐week regimen in terms of safety and efficacy.Further to this, there is now emerging evidence supporting the use of an even more hypofractionated schedule of 5 fractions delivered over 1 week as shown by the FAST‐Forward trial.7 This three‐arm trial, however, has highlighted the need for careful and meticulous attention to the dosimetry in the radiation treatment plans as the 27 Gy in 5 fraction arm resulted in higher normal tissue effects compared with the 26 Gy in 5 fraction and 40 Gy in 15 fraction arms. At 5 years, the incidence of moderate or marked clinician‐assessed normal tissue effects in the breast or chest wall was 9.9% for the 40 Gy arm, 15.4% for the 27 Gy arm
Journal of Medical Radiation Sciences – Wiley
Published: Jun 1, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.